The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity

doi:10.2174/1381612823666170522122424

	The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity
	Wang, Shuni 1,2,3; Wang, Yibing 1,2,3; Wang, Jiang1,2,3 ; Sato, Tatsunori 4; Izawa, Kunisuke 4; Soloshonok, Vadim A.5,6; Liu, Hong1,2,3
刊名	CURRENT PHARMACEUTICAL DESIGN
	2017
卷号	23 期号:30 页码:4493-4554
关键词	Hepatitis C virus (HCV) pandemic direct-acting antiviral agents (DAAs) NS3/4A protease inhibitor tailor-made amino acids structure-activity relationship (SAR) asymmetric synthesis ring-closing metathesis (RCM)
ISSN号	1381-6128
DOI	10.2174/1381612823666170522122424
文献子类	Review
英文摘要	Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them, the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development, structure-activity relationship (SAR) and their synthesis.
资助项目	National Natural Science Foundation of China[81620108027] ; National Natural Science Foundation of China[21632008] ; Major Project of Chinese National Programs for Fundamental Research and Development[2015CB910304] ; IKERBASQUE, the Basque Foundation for Science[00000000]
WOS关键词	GENOTYPE 1 INFECTION ; MICHAEL ADDITION-REACTIONS ; TREATMENT-NAIVE PATIENTS ; RING-CLOSING METATHESIS ; NUCLEOPHILIC GLYCINE EQUIVALENTS ; PEPTIDE-BASED INHIBITORS ; DYNAMIC KINETIC RESOLUTION ; CHIRAL NI(II) COMPLEX ; LARGE-SCALE SYNTHESIS ; INTERFERON-ALPHA 2A
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	BENTHAM SCIENCE PUBL LTD
WOS记录号	WOS:000416929300008
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/275691]
专题	药物化学研究室中科院受体结构与功能重点实验室新药研究国家重点实验室
通讯作者	Izawa, Kunisuke; Soloshonok, Vadim A.; Liu, Hong
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China; 3.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China; 4.Hamari Chem Ltd, Higashi Yodogawa Ku, 1-4-29 Kunijima, Osaka 5330024, Japan; 5.Univ Basque Country UPV EHU, Dept Organ Chem 1, Fac Chem, Paseo Manuel Lardizabal 3, San Sebastian 20018, Spain; 6.Basque Fdn Sci, IKERBASQUE, Alameda Urquijo 36-5,Plaza Bizkaia, Bilbao 48011, Spain
推荐引用方式 GB/T 7714	Wang, Shuni,Wang, Yibing,Wang, Jiang,et al. The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity[J]. CURRENT PHARMACEUTICAL DESIGN,2017,23(30):4493-4554.
APA	Wang, Shuni.,Wang, Yibing.,Wang, Jiang.,Sato, Tatsunori.,Izawa, Kunisuke.,...&Liu, Hong.(2017).The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity.CURRENT PHARMACEUTICAL DESIGN,23(30),4493-4554.
MLA	Wang, Shuni,et al."The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity".CURRENT PHARMACEUTICAL DESIGN 23.30(2017):4493-4554.